First-line treatment options for advanced gastric/gastroesophageal junction cancer patients with PD-L1-positive: a systematic review and meta-analysis
Open Access
- 3 May 2023
- journal article
- review article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (6) , 2875-2883
Abstract
Background: Lately, many trials have paid much attention on the oncological outcomes of immunotherapy combined with chemotherapy as a first-line treatment. The authors perform a systematic meta-analysis to assess the efficacy and safety of programmed death 1 inhibitor plus chemotherapy for first-line treatment in advanced gastric/gastroesophageal junction cancer. Materials and methods: Literature search through major databases in English and Chinese: PubMed, Embase, Cochrane library, web of Science and CNKI updated on 10 March 2023. Randomized controlled trials were selected to investigate chemotherapy plus programmed death 1 inhibitor versus chemotherapy. Results: A total of 7 randomised controlled trials including 5788 participants were included. The overall survival (hazard ratio=0.79;95% CI: 0.74–0.85, PPPPPP<0.01). Conclusion: Programmed death 1 inhibitors plus chemotherapy have significant antitumour activity compared to chemotherapy alone. However, it is riskier in terms of toxicity than chemotherapy. The authors recommend programmed death 1 inhibitors plus chemotherapy as the optimal treatment regimen for patients with positive programmed death ligand 1 expression, in Asia, male and less than 65 years of age. More well-designed studies are needed to investigate the efficacy and safety of different immune plus chemotherapy drug doses and regimens.Keywords
This publication has 51 references indexed in Scilit:
- Metronomic chemotherapy and immunotherapy in cancer treatmentCancer Letters, 2017
- An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysisClinical and Translational Oncology, 2017
- Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal modelBiochemical and Biophysical Research Communications, 2017
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative PotentialCell, 2015
- Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomasGut, 2014
- In VitroCharacterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, andIn VivoToxicology in Non-Human PrimatesCancer Immunology Research, 2014
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002